Literature DB >> 20699439

InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions.

Jennifer J Turner1, Lindsay M Morton, Martha S Linet, Christina A Clarke, Marshall E Kadin, Claire M Vajdic, Alain Monnereau, Marc Maynadié, Brian C-H Chiu, Rafael Marcos-Gragera, Adele Seniori Costantini, James R Cerhan, Dennis D Weisenburger.   

Abstract

After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, which we published in 2007. The updated hierarchical classification incorporates all of the major and provisional entities in the 2008 WHO classification, including newly defined entities based on age, site, certain infections, and molecular characteristics, as well as borderline categories, early and "in situ" lesions, disorders with limited capacity for clinical progression, lesions without current International Classification of Diseases for Oncology, 3rd Edition codes, and immunodeficiency-associated lymphoproliferative disorders. WHO subtypes are defined in hierarchical groupings, with newly defined groups for small B-cell lymphomas with plasmacytic differentiation and for primary cutaneous T-cell lymphomas. We suggest approaches for applying the hierarchical classification in various epidemiologic settings, including strategies for dealing with multiple coexisting lymphoma subtypes in one patient, and cases with incomplete pathologic information. The pathology materials useful for state-of-the-art epidemiology studies are also discussed. We encourage epidemiologists to adopt the updated InterLymph hierarchical classification, which incorporates the most recent WHO entities while demonstrating their relationship to older classifications.

Entities:  

Mesh:

Year:  2010        PMID: 20699439      PMCID: PMC2993636          DOI: 10.1182/blood-2010-06-289561

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States.

Authors:  Milena Sant; Claudia Allemani; Roberta De Angelis; Antonino Carbone; Silvia de Sanjosè; Alessandro M Gianni; Pilar Giraldo; Francesca Marchesi; Rafael Marcos-Gragera; Carmen Martos-Jiménez; Marc Maynadié; Martine Raphael; Franco Berrino
Journal:  Eur J Cancer       Date:  2008-01-31       Impact factor: 9.162

2.  A review of human carcinogens--Part B: biological agents.

Authors:  Véronique Bouvard; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi; Lamia Benbrahim-Tallaa; Neela Guha; Crystal Freeman; Laurent Galichet; Vincent Cogliano
Journal:  Lancet Oncol       Date:  2009-04       Impact factor: 41.316

3.  The utility of t(14;18) in understanding risk factors for non-Hodgkin lymphoma.

Authors:  Brian C-H Chiu; Qing Lan; Bhavana J Dave; Aaron Blair; Shelia Hoar Zahm; Dennis D Weisenburger
Journal:  J Natl Cancer Inst Monogr       Date:  2008

4.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Lisa M Rimsza; Michael L Leblanc; Joseph M Unger; Thomas P Miller; Thomas M Grogan; Daniel O Persky; Ralph R Martel; Constantine M Sabalos; Bruce Seligmann; Rita M Braziel; Elias Campo; Andreas Rosenwald; Joseph M Connors; Laurie H Sehn; Nathalie Johnson; Randy D Gascoyne
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

5.  Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone.

Authors:  Andrew L Feldman; Daniel A Arber; Stefania Pittaluga; Antonio Martinez; Jerome S Burke; Mark Raffeld; Mireia Camos; Roger Warnke; Elaine S Jaffe
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

6.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

7.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes.

Authors:  Lindsay M Morton; Sophia S Wang; Wendy Cozen; Martha S Linet; Nilanjan Chatterjee; Scott Davis; Richard K Severson; Joanne S Colt; Mohammad A Vasef; Nathaniel Rothman; Aaron Blair; Leslie Bernstein; Amanda J Cross; Anneclaire J De Roos; Eric A Engels; David W Hein; Deirdre A Hill; Linda E Kelemen; Unhee Lim; Charles F Lynch; Maryjean Schenk; Sholom Wacholder; Mary H Ward; Shelia Hoar Zahm; Stephen J Chanock; James R Cerhan; Patricia Hartge
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

8.  Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.

Authors:  Wing-yan Au; Dennis D Weisenburger; Tanin Intragumtornchai; Shigeo Nakamura; Won-Seog Kim; Ivy Sng; Julie Vose; James O Armitage; Raymond Liang
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

9.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.

Authors:  Karin Ekström Smedby; Claire M Vajdic; Michael Falster; Eric A Engels; Otoniel Martínez-Maza; Jennifer Turner; Henrik Hjalgrim; Paolo Vineis; Adele Seniori Costantini; Paige M Bracci; Elizabeth A Holly; Eleanor Willett; John J Spinelli; Carlo La Vecchia; Tongzhang Zheng; Nikolaus Becker; Silvia De Sanjosé; Brian C-H Chiu; Luigino Dal Maso; Pierluigi Cocco; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Scott Davis; Richard Severson; James R Cerhan; Elizabeth C Breen; Brenda Birmann; Andrew E Grulich; Wendy Cozen
Journal:  Blood       Date:  2008-02-08       Impact factor: 22.113

Review 10.  Helicobacter Pylori associated global gastric cancer burden.

Authors:  Sam M Mbulaiteye; Michie Hisada; Emad M El-Omar
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  109 in total

1.  A prospective analysis of blood donation history and risk of non-Hodgkin lymphoma.

Authors:  Kazusa Ishii; Brenda M Birmann; Xuehong Zhang; Edward Giovannucci; Kimberly A Bertrand
Journal:  Leuk Lymphoma       Date:  2015-10-16

2.  Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.

Authors:  Nadia Howlader; Lindsay M Morton; Eric J Feuer; Caroline Besson; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-15       Impact factor: 4.254

3.  Dicamba use and cancer incidence in the agricultural health study: an updated analysis.

Authors:  Catherine C Lerro; Jonathan N Hofmann; Gabriella Andreotti; Stella Koutros; Christine G Parks; Aaron Blair; Paul S Albert; Jay H Lubin; Dale P Sandler; Laura E Beane Freeman
Journal:  Int J Epidemiol       Date:  2020-08-01       Impact factor: 7.196

4.  Meat intake is not associated with risk of non-Hodgkin lymphoma in a large prospective cohort of U.S. men and women.

Authors:  Carrie R Daniel; Rashmi Sinha; Yikyung Park; Barry I Graubard; Albert R Hollenbeck; Lindsay M Morton; Amanda J Cross
Journal:  J Nutr       Date:  2012-04-25       Impact factor: 4.798

5.  Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation.

Authors:  Christina A Clarke; Sally L Glaser; Scarlett L Gomez; Sophia S Wang; Theresa H Keegan; Juan Yang; Ellen T Chang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

6.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

7.  A prospective analysis of circulating saturated and monounsaturated fatty acids and risk of non-Hodgkin lymphoma.

Authors:  Yu-Han Chiu; Kimberly A Bertrand; Shumin Zhang; Francine Laden; Mara M Epstein; Bernard A Rosner; Stephanie Chiuve; Hannia Campos; Edward L Giovannucci; Jorge E Chavarro; Brenda M Birmann
Journal:  Int J Cancer       Date:  2018-08-10       Impact factor: 7.396

8.  Prediagnostic serum tocopherol levels and the risk of non-hodgkin lymphoma: the multiethnic cohort.

Authors:  Yukiko Morimoto; Nicholas J Ollberding; Robert V Cooney; Lynne R Wilkens; Adrian A Franke; Loïc Le Marchand; Marc T Goodman; Brenda Y Hernandez; Laurence N Kolonel; Gertraud Maskarinec
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

9.  Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS").

Authors:  Eric A Engels; Ruth Parsons; Caroline Besson; Lindsay M Morton; Lindsey Enewold; Winnie Ricker; Elizabeth L Yanik; Hannah Arem; April A Austin; Ruth M Pfeiffer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-26       Impact factor: 4.254

10.  Erythrocyte membrane fatty acid composition, serum lipids, and non-Hodgkin's lymphoma risk in a nested case-control study: the multiethnic cohort.

Authors:  Yukiko Morimoto; Shannon M Conroy; Nicholas J Ollberding; Susanne M Henning; Adrian A Franke; Lynne R Wilkens; Marc T Goodman; Brenda Y Hernandez; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel; Gertraud Maskarinec
Journal:  Cancer Causes Control       Date:  2012-08-21       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.